NSRX · Nasus Pharma Ltd · Financials
Market Cap
$39.88M
Shares
11.71M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$1.24B
FY2025
Net Income
-$5.86M
-282.2%
FY2025
Operating Margin
-0.4%
FY2025
Diluted EPS
-$0.72
-227.3%
FY2025
Operating Cash Flow
-$4.92M
-639.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| $1.24B | — | — | |
| $2.24M | $335K | $567K | |
| $2.67M | $743K | $580K | |
| $4.9M | $1.08M | $1.15M | |
| -$4.9M | -$1.08M | -$1.15M | |
| -0.4% | — | — | |
| -$78K | $29K | $49K | |
| -$5.86M | -$1.53M | -$1.05M | |
| -0.47% | — | — | |
| $5.86M | $1.53M | $1.05M | |
| USD/shares | -$0.72 | -$0.22 | -$0.15 |
| USD/shares | -$0.72 | -$0.22 | -$0.20 |
| shares | 8.01M | 7.03M | 6.89M |
| shares | 8.01M | 7.03M | 7.06M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.